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Abstract
Background: Hypothyroidism (sub-clinical and overt) and metabolic syndrome are recognized risk factors for
atherosclerotic cardiovascular disease. This study is an effort to identify the proposed association between these
two disease entities and the risk factors involved in this association.
Methods: A cross – sectional study from a tertiary care teaching hospital in Chennai city, South India. 420
patients with metabolic syndrome (NCEP – ATP III criteria) were included in the study group. 406 appropriately
age and sex matched controls having no features of metabolic syndrome (0 out of the 5 criteria) were compared
with the study group. The study extended over a 5 year period. TSH, FT4 were measured for both the groups
using electrochemiluminescence immuno assay. HsCRP was measured for all the patients in the study group. The
baseline characteristics between the groups were compared with Student's't' test. Chi-square test was used to
analyze the association between metabolic syndrome and hypothyroidism (overt and sub-clinical). Logistic
regression analysis was applied to identify the association between hypothyroidism and the patient characteristics
in the study group.
Results: Of the 420 patients in the study group, 240 were females (57.1%), 180 were males (42.9%) with mean
age 51 ± 9.4 years. Of the 406 patients in the control group, 216 were females (53.2%), 190 males (46.8%) with
mean age 49 ± 11.2 years. In the study group, 92 had sub-clinical hypothyroidism (SCH) (21.9%), 31 were overtly
hypothyroid (7.4%) and 297 were euthyroid (70.7%). In the control group 27 patients had sub-clinical
hypothyroidism (6.6%), 9 patients had overt hypothyroidism (2.2%) and 370 patients were euthyroid (91.2%). On
comparison SCH (P < 0.001) and overt hypothyroidism (P < 0.001) were significantly associated with the study
group as compared to the control group. Logistic regression analysis recognized the association between female
gender (P = 0.021) and HsCRP (P = 0.014) with sub-clinical hypothyroidism and female gender (P = 0.01) with
overt hypothyroidism in the study group.
Conclusion: Hypothyroidism is associated with metabolic syndrome and females are more at risk. Metabolic
syndrome patients with a raised HsCRP are at significant risk of having sub-clinical hypothyroidism.
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Background
Metabolic syndrome constitutes a cluster of risk factors
characterized by hypertension, atherogenic dyslipidemia,
hyperglycemia, prothrombotic and proinflammatory con-
ditions [1]. As early as 1923, Kylin described the clustering
of hyperuricemia, hyperinsulinemia and hypertension
[2]. In 1988, during the seminal Banting lecture, Reaven
described the central role of insulin resistance in syn-
drome X, which has now become known as the metabolic
syndrome [3]. It was also referred to as insulin resistance
syndrome by some until 1999, when the WHO named it
metabolic syndrome as there was not sufficient evidence
to show that all its components were caused by insulin
resistance [4].
Metabolic syndrome (MetS) affects approximately one
quarter of the population in developed countries. Its pres-
ence is a major risk for development of both type 2 diabe-
tes mellitus and atherosclerosis. The prevalence of
cardiovascular disease is 2–3 times higher in individuals
with metabolic syndrome than in age-matched controls
[5]. According to CURES 52 study, hypertension is preva-
lent in 20% of Chennai urban population [6]. Among
these hypertensive patients, the prevalence of other com-
ponents of metabolic syndrome was: diabetes in 31.8%,
impaired glucose tolerance in 17.9%, hypercholestero-
lemia in 38.8%, hypertryglyceridemia in 38%, abdominal
obesity in 64.3% and general obesity in 40% [6]. The
Jaipur Heart Watch Studies have reported that in urban
Indian populations, age-adjusted prevalence of metabolic
syndrome was 18.4% in men, 30.9% in women, and
24.9% overall [7].
Sub-clinical hypothyroidism (SCH) and overt hypothy-
roidism are recognized risk factors for atherosclerotic car-
diovascular disease, hyperlipidemia, low grade
inflammation and hypercoagulability [8-10]. There is
scanty data on the prevalence and the various associations
of SCH and overt hypothyroidism in the South Indian
general population.
As metabolic syndrome and hypothyroidism are inde-
pendent risk factors for the same disease process, namely
cardiovascular disease, it is possible that patients suffering
from both these disease entities may have a compounded
risk. Our study is an effort to investigate the proposed
association between these two disease entities and to
identify the factors that increase the risk of this associa-
tion.
Systemic inflammation measured by high sensitivity C
reactive protein (HsCRP) is a known risk factor for cardi-
ovascular disease. Association between metabolic syn-
drome and HsCRP has been clearly identified and a recent
Japanese study has redefined metabolic syndrome with
HsCRP as a component in this definition [11,12]. In this
study, we have tried to answer the question whether met-
abolic syndrome patients with a raised HsCRP have an
increased risk of having hypothyroidism.
Methods
This cross sectional study was conducted in an outpatient
general medicine clinic of a tertiary care teaching hospital
in Chennai, South India. 420 patients with metabolic syn-
drome (MetS) who fulfilled the NCEP-ATP III criteria (3
out of 5 criteria positive namely blood pressure > or =
130/85 mm hg or on antihypertensive medications, fast-
ing plasma glucose > 110 mg/dl or on anti-diabetic med-
ications, fasting triglycerides > 150 mg/dl, HDL < 40 mg/
dl in males and <50 mg/dl in females, waist circumference
> 102 cms in men and 88 cms in women) were included
in the study group [13]. 406 patients who had no features
of metabolic syndrome (0 out of 5 criteria for metabolic
syndrome) were included in the control group. The study
extended over a 5 year period (June 2003 to June 2008).
Patients with liver disorders, renal disorders, congestive
cardiac failure, pregnant women, patients on oral contra-
ceptive pills, statins and other medications that alter thy-
roid functions and lipid levels were excluded from the
study. Patients who were diagnosed as having hyperthy-
roidism, sub-clinical hyperthyroidism and those who are
under treatment for any thyroid related disorder were
excluded from the study. From both the study and the
control group baseline demographic data were collected
and a detailed physical examination was performed.
Blood pressure was measured over the right arm with the
patient lying supine. 3 readings were taken and a mean
value of the 3 readings was taken as the final recording.
Waist circumference was measured at the plane between
anterior superior iliac spines and lower costal margin at
the narrowest part of the waistline while the patient was
standing and during expiration. Fasting blood samples
were obtained (venous blood samples taken after over-
night fast of a minimum of 8 hrs); glucose, total choles-
terol, HDL cholesterol and triglyceride levels were
determined. LDL was calculated using Friedwald formula
[14]. Serum TSH and FT4 measurements were made using
Roche elecsys modular analytics E 170 using electrochem-
iluminescence immuno assay (ECLIA method). The ana-
lytical sensitivity of TSH was 0.005 μIU/ml and for FT4
was 0.023 ng/dl. Normal range for TSH was (0.27–4.2)
μIU/ml and for FT4 was (0.93–1.7) ng/dl. A high serum
TSH level (range between 4.2 μIU/ml to 10 μIU/ml) and
a normal free thyroxine (FT4) level were required for the
diagnosis of sub-clinical hypothyroidism (SCH) [15].
Patients with high TSH (> 10 μIU/ml) and low FT4 levels
(< 0.93 ng/dl) were classified as being overt hypothyroid.
Patients with normal TSH and FT4 were considered euthy-
roid. Plasma levels of HsCRP were assessed using vali-
dated high sensitivity assay (Dade Behring N highThyroid Research 2009, 2:2 http://www.thyroidresearchjournal.com/content/2/1/2
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sensitivity CRP assay, Marburg, Germany), with a coeffi-
cient of variation of 3.6%. Reference range < 3.0 mg/l.
Informed consent was obtained from all the study partic-
ipants and the ethics committee of our tertiary care hospi-
tal approved the study. Baseline characteristics of the
study participants were expressed in mean ± SD and per-
centage. Student's 't' test was used to analyze differences in
baseline characteristics between the study group and the
control group. Chi-square test was used to analyze the
association between metabolic syndrome and hypothy-
roidism (overt and sub-clinical). Associations between
patient characteristics (age, gender, smoking status, alco-
hol consumption, mean systolic blood pressure, mean
diastolic blood pressure, waist circumference, total cho-
lesterol, HDL cholesterol, LDL cholesterol, triglycerides,
fasting blood sugar, HsCRP) and hypothyroidism (overt
and sub-clinical) in the study group were analyzed using
multiple logistic regression. P-value of < 0.05 was consid-
ered statistically significant. Statistical analysis was per-
formed using SPSS windows version 16.0 software (SPSS
Inc., Chicago, Illinois).
Results
Of the 420 patients in the study group, 240 were females
(57.1%) and 180 were males (42.9%) with mean age 51
± 9.4 years. The control group (n = 406) had 216 females
(53.2%) and 190 males (46.8%) with mean age 49 ± 11.2
years. The baseline characteristics of the two groups are
depicted in (Table 1). The two groups were similar with
respect to age, sex, smoking and alcohol use (P > 0.05).
However mean systolic pressure, diastolic pressure, waist
circumference, fasting blood sugar, total cholesterol, LDL
cholesterol, triglycerides, TSH and HsCRP values were sig-
nificantly higher in the study group compared to the con-
trol group. HDL cholesterol and FT4 values were
significantly lower in the study group (Table 1).
In the study group, 92 had sub-clinical hypothyroidism
(21.9%), 31 were overtly hypothyroid (7.4%) and 297
were euthyroid (70.7%). In the control group 27 had sub-
clinical hypothyroidism (6.6%), 9 had overt hypothy-
roidism (2.2%) and 370 were euthyroid (91.2%). Hence
on comparison SCH (P < 0.001) and overt hypothy-
Table 1: Patient Characteristics
MetS Group (n = 420) Control group (n = 406) Significance (P)
Age (year) 51 ± 9.4 years 49 ± 11.2 years 0.071
Gender (n)
Males 180 190 0.51
Females 240 216
Smoking (n) 169 190 0.321
Alcohol (n) 148 153 0.256
Systolic BP (mmhg) 140.8 ± 5.4 121.3 ± 3.1 0.001
Diastolic BP (mmhg) 90.7 ± 8.5 84 ± 5.73 0.001
Waist circumference (cms) 100.1 ± 5.72 84.2 ± 6.91 0.001
Total cholesterol (mg/dl) 225.9 ± 26.7 191.4 ± 31.2 0.012
HDL cholesterol (mg/dl) 40.2 ± 8.9 46.5 ± 5.76 0.031
LDL cholesterol (mg/dl) 135.9 ± 21.5 109.3 ± 18.6 0.028
Triglycerides (mg/dl) 174.7 ± 58.9 121.6 ± 67.2 0.0001
Fasting Blood Sugar (mg/dl) 109.8 ± 12.8 98.5 ± 9.87 0.031
FT4 (ng/dl) 1.12 ± 0.7 1.3 ± 0.6 0.041
TSH (μIU/ml) 6.1 ± 4.21 5.3 ± 4.89 0.023
HsCRP (mg/l) 2.8 ± 1.9 0.9 ± 1.23 0.001Thyroid Research 2009, 2:2 http://www.thyroidresearchjournal.com/content/2/1/2
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roidism (P < 0.001) were significantly associated with the
study group as compared to the control group.
Logistic regression analysis recognized the association
between female gender (P = 0.021, CI: 1.912–12.112) and
HsCRP (P = 0.014, CI: 1.587–6.482) with sub-clinical
hypothyroidism (Table 2); and female gender (P = 0.01,
CI: 1.912 – 2.241) was associated with hypothyroidism in
the study group (Table 3).
Discussion
Our study has shown a high prevalence of SCH (21.9%)
and overt hypothyroidism (7.4%) in patients with meta-
bolic syndrome. In our control group 6.6% had SCH and
2% had overt hypothyroidism. A large multi-centered
study on pediatric population from 10 states in India has
shown an overall goiter prevalence of 4.78% with
extremes of prevalence namely 31.02% and 0.02% being
noted in 2 districts [16]. A recent review has identified the
prevalence of sub-clinical hypothyroidism to be 4% to 8%
in the general population, and up to 15% to 18% in
women who were over 60 years of age in the western pop-
ulation [17]. However data is lacking with respect to the
population prevalence of hypothyroidism in the adult
South Indian population.
In our study mean systolic pressure, diastolic pressure,
waist circumference, fasting blood sugar, total cholesterol,
LDL cholesterol, triglycerides and TSH values were signif-
icantly higher in the MetS group compared to the control
group. Our study has also shown a strong association
between SCH and overt hypothyroidism with MetS. Simi-
lar to our observation the study by Uzunlulu et al. [18],
had shown SCH prevalence to be 16.4% (n = 36) in the
MetS group (n = 220). The MetS group in their study had
significantly higher levels of mean systolic pressure,
diastolic pressure, waist circumference, body mass index,
fasting blood sugar, total cholesterol, LDL cholesterol,
triglycerides and TSH values. SCH was significantly asso-
ciated with MetS group (P = 0.001). However this study
did not address patients with overt hypothyroidism and
all observations were on SCH patients only.
Supporting our observations thyroid function has been
consistently associated with individual components of
metabolic syndrome. Recent studies have established the
association between FT4 levels and total cholesterol, LDL
cholesterol, HDL cholesterol, and triglycerides [19,20],
and SCH is also associated with an increased level of Lipo-
protein (a) [21]. The HUNT study concluded that "Within
the range of TSH that is considered clinically normal,
increasing level of TSH was associated with less favorable
lipid concentrations. The association with serum lipids
was linear across the entire reference range of TSH" [22].
Table 2: Association between patient characteristics and sub-clinical hypothyroidism in the study group (Logistic regression analysis)
Odds ratio Confidence interval Significance
Gender 6.201 (1.912–12.112) 0.021
Smoking status 0.221 (0.276–4.511) 0.312
Age 0.421 (0.451–1.112) 0.133
Alcohol consumption 0.312 (0.812–3.116) 0.124
Waist circumference 2.112 (0.621–1.863) 0.41
Systolic blood pressure 0.781 (0.539–1.221) 0.061
Diastolic blood pressure 0.314 (0.351–3.951) 0.276
Total cholesterol 1.817 (1.541–1.921) 0.213
Triglycerides 0.154 (0.143–1.112) 0.062
HDL cholesterol 1.217 (0.427–4.332) 0.344
Fasting Blood Sugar 0.312 (0.811–2.435) 0.371
HsCRP 1.84 (1.587–6.482) 0.014Thyroid Research 2009, 2:2 http://www.thyroidresearchjournal.com/content/2/1/2
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With regard to other components of MetS, a low normal
FT4 level was significantly associated with increased insu-
lin resistance [19] and SCH has been associated with fast-
ing hyperinsulinemia [23]. Diastolic arterial pressure has
been significantly associated with TSH levels and T4 resist-
ance-index (freeT4.TSH product) [24]. Hence in summary
hypothyroidism is significantly associated with every indi-
vidual component of metabolic syndrome.
In our study females with metabolic syndrome had signif-
icant association with SCH and overt hypothyroidism.
The study by Uzunlulu et al. had also shown females to be
associated with SCH and MetS [18]. A study from the
United States has shown that among older white women,
high TSH was associated with deleterious changes in
serum lipids, particularly HDL-C, LDL-C, and the ratio of
LDL-C to HDL-C cholesterol. Women with multiple lipid
abnormalities were twice as likely to have an increased
TSH [25]. The HYOGA study has shown that hypercholes-
terolemic women >50 years of age with SCH had symp-
toms of hypothyroidism and a poorer quality of life even
when TSH was less than 10 mIU/L [26]. Hence it may be
a good practice to screen females with metabolic syn-
drome for hypothyroidism.
In our study HsCRP was found to be associated with sub-
clinical hypothyroidism in patients with metabolic syn-
drome. Previous published studies reflect a conflicting
observation on the association between HsCRP and
hypothyroidism. Tuzcu et al. and Christ-Crain et al. have
shown a clear association between hypothyroidism and a
raised HsCRP [23,27]. In contrary, Pearce et al. had shown
that patients with Hashimoto's thyroiditis, short term
hypothyroidism and post partum thyroiditis had similar
HsCRP as compared to their euthyroid controls and that
HsCRP levels may have only a limited role in the diagno-
sis of thyroid diseases [28]. The Study by Hueston et al.
also showed no difference in HsCRP levels between
patients with SCH and euthyroid individuals [29]. The
important difference between these studies and our study
is that all our study patients had metabolic syndrome
whereas the other studies did not address patients with
metabolic syndrome.
With respect to the association between vascular disease
and raised HsCRP in hypothyroid patients, Nagasaki et al.
showed that hypothyroid patients with a raised HsCRP
have increased stiffness of the common carotid artery
[30]. Similarly studies have shown HsCRP to be an addi-
tional risk factor for cardiovascular disease in hypothyroid
patients [27]. The compounded cardiovascular risk that
patients with metabolic syndrome, hypothyroidism and
systemic inflammation (raised HsCRP) will suffer is yet to
be determined. However Framingham off spring study
had shown that the combined cardiovascular risk in
patients with metabolic syndrome and a raised HsCRP
Table 3: Association between patient characteristics and overt hypothyroidism in the study group (Logistic regression analysis)
Odds ratio Confidence interval Significance
Gender 2.121 (1.912 – 2.241) 0.01
Smoking status 0.319 (0.112–2.311) 0.256
Age 0.223 (0.112–1.106) 0.141
Alcohol consumption 0.418 (0.817–3.222) 0.067
Waist circumference 2.112 (0.221–2.167) 0.296
Systolic blood pressure 0.265 (0.522–2.977) 0.067
Diastolic blood pressure 1.911 (0.481–3.219) 0.413
Total cholesterol 0.144 (0.544–3.227) 0.129
Triglycerides 0.671 (0.511–1.371) 0.133
HDL cholesterol 1.117 (0.283–2.947) 0.216
Fasting blood Sugar 0.591 (0.687–1.395) 0.164
HsCRP 0.431 (0.586–1.223) 0.061Thyroid Research 2009, 2:2 http://www.thyroidresearchjournal.com/content/2/1/2
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were similar and not worse when compared to their indi-
vidual risks [11].
The Tromso Study [20] and the Basel Thyroid Study [31]
have shown that L-thyroxine replacement in patients with
sub-clinical hypothyroidism has a beneficial effect on low
density lipoprotein cholesterol levels and clinical symp-
toms of hypothyroidism. Also an important risk reduction
in cardiovascular mortality of 9–31% can be estimated
from the observed improvement in low density lipopro-
tein cholesterol [22,23]. Raising significant doubts about
this estimated cardiovascular risk reduction a recent
review which analyzed data from twelve trials conducted
on levothyroxine replacement in sub-clinical hypothy-
roidism concluded that though thyroxine replacement
improves some parameters in lipid profile and left ven-
tricular function, this did not translate into improved sur-
vival and decreased cardiovascular morbidity [17].
However these trials did not address the issue of thyroxine
replacement in patients with sub-clinical hypothyroidism
in the setting of metabolic syndrome. Hence further rand-
omized trials have to be planned in this line to determine
the efficacy of thyroxine replacement in this group of
patients.
Data is again conflicting with respect to the effect of thy-
roxine replacement on HsCRP levels in hypothyroid
patients. In the study by Christ-Crain et al. thyroxine
replacement did not alter HsCRP levels [27], whereas
Nagasaki et al. observed a reduction of HsCRP levels with
thyroxine replacement and it predicted improvement of
arterial thickness in their study cohort [30].
Conclusion
Sub-clinical and overt hypothyroidism is significantly
associated with metabolic syndrome patients. Females
have an increased risk of this association. Hence it will be
worthwhile to screen female metabolic syndrome patients
for hypothyroidism. MetS patients with SCH may have
systemic inflammation and conversely, MetS patients
with raised HsCRP are at risk for SCH. Whether this triple
association between MetS, hypothyroidism, systemic
inflammation will translate into compounded cardiovas-
cular risk is yet to be determined. Controversy prevails
with respect to benefits of thyroxine replacement in sub-
clinical hypothyroidism. Whether metabolic syndrome
patients with sub-clinical hypothyroidism will benefit
from thyroxine replacement is for future randomized tri-
als to answer.
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